VIDEO: Advancements in AMD treatment

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.

There have been a variety of advancements in the treatment of both dry and wet macular degeneration. On the wet side, there has been improvements in our ability to deliver drugs that have a sustained suppression of vascular endothelial growth factor. And that is the form of two different things. First and foremost, there was the approval of SUSVIMO, which is an implant made by Roche's Genentech. It delivers a 100 ng/mL of Lucentis in a vial that is delivered through the pars plana into the vitreous cavity. And has been shown to have, in most patients, about an 80% rate of suppression at six months of time. And it was recently improved by the FDA and it is an exciting advancement in the treatment of neovascular AMD. The second big advancement has been in the new mechanism of action category, where we've seen improvements in the therapy with both anti-VEGF, as well as a Ang-2 effect, Ang-2 inhibition effect. And that's a bispecific molecule called VABYSMO. And this is also a Roche's Genentech product that's just recently been FDA released, and now been used the past few weeks, and really has shown a lot of promise at giving a lot of durability. In fact, clinical trial show that almost 78% of patients were able to achieve a q12 interval dosing or longer with VABYSMO compared to the market leader, which is EYLEA.